Harvard Bioscience (HBIO, Financial) experienced a significant drop, falling 5.31%. The stock is now priced at $2.32 per share with a trading volume of 89,737 shares and a turnover rate of 0.21%. The stock's amplitude reached 4.49% during this period.
Recent financial reports reveal Harvard Bioscience had a revenue of $21.97 million, a net loss of $4.80 million, and an earnings per share (EPS) of -$0.11. The company's gross profit stood at $11.43 million, and it currently has a price-to-earnings (P/E) ratio of -7.06. Despite these figures, all participating institutions continue to recommend buying the stock without any hold or sell suggestions.
In the broader medical devices sector, which saw an overall decline of 0.77%, other stocks such as Stereotaxis, Inc., Glucotrack, Inc., and Innovative Eyewear Inc showed significant gains. Moreover, stocks like Sharps Technology Inc., Nexgel, Inc., and Bionano Genomics, Inc. were particularly active, with turnover rates of 3.55%, 3.53%, and 2.54% respectively. Notable price volatility was observed in Innovative Eyewear Inc, Glucotrack, Inc., and Zhongjin Medical, with amplitudes of 40.67%, 26.24%, and 20.36% respectively.
Harvard Bioscience Inc specializes in developing, manufacturing, and selling technologies and specialty products for drug development, focusing on fundamental research, discovery, and preclinical testing. Known for its scientific instruments, the company operates in North America, Europe, and China, reaching global customers through direct sales and distribution channels. Its prominent product brands include Harvard Apparatus, DSI, Buxco, and more, with most revenue generated in the United States.
